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ABSTRACT
Objective: To assess the effect of a protocol-based pharmacist intervention on blood pressure 
control and medication adherence among treated hypertensive patients who are users of 
community pharmacies. 
Methods: A quasi experimental study design with control group has been designed to compare 
the effect of pharmaceutical intervention (intervention group) versus the standard healthcare 
procedure (control group) on blood pressure and medication adherence among hypertensive 
patients receiving drug therapy in community pharmacies. The patients will be allocated evenly 
between the two groups (ncontrol = nintervention), with a 6-month follow-up. The pharmaceutical 
intervention program will comprise three main parts: 1) patient education / information on issues 
relating to hypertension and medication adherence; 2) self-monitoring of blood pressure; and 3) 
interaction with the physician through personalized reports when the mean blood pressure values 
recorded at home exceed the treatment goal according to the clinical condition of the patient. 
In order to evaluate the effect of the pharmaceutical intervention upon medication adherence 
and blood pressure, blood pressure recordings will be made in the pharmacy, while percent 
medication adherence will be established based on pill count in both groups at the start and end 
of the study.
Discussion: To our knowledge, this is the first study in the community pharmacy setting in Spain 
to evaluate the effectiveness of pharmaceutical intervention in combination with home blood 
pressure monitoring on blood pressure control. In addition, the pharmaceutical intervention has 
been designed for inclusion as standard practice in the context of Pharmaceutical Care.
KEY WORDS. Hypertension, adherence, community pharmacy services, intervention, home 
blood pressure monitoring.
RESUMEN
Objetivo: Evaluar el efecto de una intervención farmacéutica protocolizada sobre el control de la 
presión arterial y la adherencia al tratamiento farmacológico en pacientes usuarios de farmacias 
comunitarias. 
Material y métodos: Estudio cuasi-experimental con grupo control en el que se comparará el 
efecto de una intervención farmacéutica (grupo intervención) con el proceso de atención habitual 
(grupo control), sobre la presión arterial y la adherencia al tratamiento de pacientes hipertensos 
tratados farmacológicamente en farmacias comunitarias. Los pacientes serán distribuidos de 
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forma equitativa en ambos grupos (n control = n intervención) y serán seguido durante 6 meses. 
El programa de la intervención farmacéutica constará de tres partes fundamentales: 1) educación/
información al paciente sobre aspectos relacionados con la hipertensión y adherencia al tratamiento 
farmacológico, 2) automonitorización de la presión arterial y, 3) interacción con el médico mediante 
informes personalizados cuando la media de las cifras de presión arterial realizadas en el domicilio 
superen el objetivo terapéutico acorde con la situación clínica del paciente.  Para evaluar el efecto de la 
intervención farmacéutica sobre la adherencia terapéutica y la presión arterial se obtendrán medidas 
de presión arterial en la farmacia y porcentaje de cumplimiento terapéutico mediante recuento de 
comprimidos en ambos grupos al principio y al final del estudio.
Discusión: Según nuestros conocimientos, éste es el primer estudio que se realiza en farmacia 
comunitaria en España para probar la efectividad de una intervención farmacéutica conjuntamente 
con la automedida de la presión arterial sobre el control de la presión arterial. Además, la intervención 
farmacéutica se ha diseñado de forma que pueda integrase como práctica habitual enmarcada dentro 
de la Atención Farmacéutica.
PALABRAS CLAVE: Hipertensión, adherencia, servicios farmacéuticos, intervención, automedida 
domiciliaria de la presión arterial.
BACKGROUND
Hypertension is a major public health problem. Its 
prevention and control are therefore a key objectives for 
the healthcare system1, 2.
In Spain, the prevalence of hypertension in the general 
population is estimated to be 35%, affecting a total of 10 
million people throughout the country. Specifically, 40% of 
these patients are middle aged, and 60% are over 60 years 
old3. 
Drug treatment for lowering blood pressure (BP) has 
been shown to significantly reduce the risk of ischemic 
stroke by 31-45%, and the risk of myocardial infarction 
by 8-23%4. However, despite the availability of effective 
antihypertensive drugs, the control of high BP is far 
from optimum in this country, since less than 50% of all 
hypertensive patients are controlled3.
Difficulties in accessing the healthcare services, non-
adherence, inadequate practice organization and physician 
practice patterns are some of the causes related to the 
lack of BP control5, 6. In order to solve these problems, 
the World Health Organization, the International Society 
of Hypertension and other societies (American Society 
of Hypertension, European Society of Hypertension, 
and Canadian Hypertension Society) recommend the 
development of strategies involving the implication and 
participation of all those healthcare professionals that 
attend such patients 7-9.
Community pharmacists are the most accessible 
healthcare professionals in Spain. In addition, as a result 
of their specific training, they are the ideal professionals 
for advising patients on proper drug use. These reasons 
justify the integration of community pharmacists in the 
multidisciplinary healthcare team setting, where they 
should play an active role in the follow-up of hypertensive 
patients with a view to enhancing compliance, reducing 
adverse events and improving blood pressure control10. In 
this regard, the healthcare activities inherent to pharmacists, 
set within the concept of Pharmaceutical Care11-13, could be 
a good option to be taken into account for improving BP 
control and medication adherence. Specifically, a number 
of studies have shown that BP control can be improved 
when the pharmacist is involved in monitoring patient’s 
BP, offers advice on home blood pressure monitoring 
(HBPM), provides information on the disease, promotes 
changes in lifestyle and habits, encourages medication 
adherence and/or provides recommendations on the 
pharmacotherapeutic adjustments considered appropriate, 
in collaboration with the physician5,14-24.
In a recent systematic review of interventions used to 
improve control of BP in hypertensive patients25, the 
authors discussed the need to implement protocols for 
hypertensive patient follow-up, and advocated for the 
promotion of HBPM and for appointment reminders 
as part of the strategy to improve BP control. Moreover, 
the authors concluded that pharmacist-led care requires 
further evaluation.
Three systematic reviews recently published, whose 
objective were to evaluate the impact of pharmacists´ 
interventions in the management of hypertensive patients14-
16, highlighted that the studies carried out in a community 
pharmacy setting are scarce and have limitations that 
should be solved. Firstly, only one study17 used a reliable 
method to measure antihypertensive medication adherence. 
Secondly, only two studies6,26 integrated HBPM as a part of 
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the community pharmacist intervention. Moreover, these 
studies presented a number of limitations such as: short-
time period of follow-up (3 months), lack of a control group 
or didn’t show the proportion of patients with controlled 
hypertension at the end of the study. As it is well known, 
HBPM may increase patients’ involvement in their care, 
also increasing medication adherence and improving blood 
pressure control27-31. Furthermore, community pharmacists 
can play an important role in the implementation of HBPM 
in daily practice29,32-34.
Therefore new studies are needed in a community 
pharmacy setting to draw conclusive data on the benefits 
of pharmacist intervention in the control of BP and 
antihypertensive medication adherence.
With the purpose of improving the quality of the research 
published to date, this study protocol is aimed at 
providing detailed information on the development of the 
AFenPA pilot study, specifically, as regards: study design, 
calculation of the sample size, operational definition of 
the variables, and operating procedures with a detailed 
definition of the pharmaceutical intervention or statistical 
data analysis, amongst others. 
Hypothesis: Pharmacist intervention together with HBPM 
can improve BP control and medication adherence as 
compared to routine practice in the pharmacy.
Study aims and objectives: To assess the effect of a 
protocol-based pharmacist intervention on: 1) the control of 
hypertension; 2) reduction of systolic and/or diastolic BP; 
and 3) medication adherence among treated hypertensive 
patients who are users of community pharmacies. 
METHODS
Study design. A quasi experimental study design with 
control group has been designed to compare the effect of 
pharmaceutical intervention (intervention group) versus 
the usual care procedure in community pharmacies 
(control group) upon BP and medication adherence. Each 
patient will be followed for 6 months. 
Study Setting. Community pharmacies of the provinces of 
Jaén and Granada (Spain). 
Community pharmacists’ eligibility criteria. Community 
pharmacists that meet all the following criteria will be 
eligible to participate in the AFenPA study: 
•Pharmacists with previous research experience.  
•Pharmacists whose pharmacies have a private 
counselling area where patients will be shielded from the 
public eye and ear, and
•Pharmacists able to carry out a follow-up phase for 
patients during at least six months. 
Recruitment of community pharmacists. Community 
pharmacists will be identified through the local professional 
pharmacy associations of Jaén and Granada, which will 
contact pharmacists of their provinces to inform them 
about the project. Pharmacists who agree to participate 
will sign the appropriate commitment document and will 
be instructed on hypertension, medication adherence and 
the development of the project.” 
In order to minimize the risk of contamination between the 
intervention and the control group, trainers will emphasize 
that patients included in the control group should only 
receive usual care.
Subjects. The study population will include hypertensive 
patients receiving drug therapy.
Patient inclusion criteria. Patients of either sex, aged 18-80 
years who visit the pharmacy with a personal prescription 
for any antihypertensive drug.
Patient exclusion criteria. Patients living with other 
subjects who are taking the same antihypertensive drug(s), 
pregnant women, patients who during the screening 
process at the pharmacy show a mean systolic / diastolic 
BP of ≥ 180/110 mmHg, subjects with difficulties for 
HBPM or where such monitoring is not recommended, 
patients lacking motivation for self-control, with secondary 
hypertension, recent cardiovascular events (less than 6 
months), renal or liver insufficiency, patients who have 
started or have switched their antihypertensive treatment 
within less than one month, subjects already enrolled in a 
special hypertensive patient program, or subjects used to 
performing HBPM at least two days a month.
Any patient who approaches and declines to participate or 
eventually abandons the study, will be included in a list in 
order to carry out a non-responder analysis of patients will 
regard to socio-demographic and clinical data.
Sample size. Sample size determination was based on 
the difference in the expected percentage of subjects with 
controlled hypertension between the control group and the 
intervention group, at the end of the study. The prevalence 
of controlled hypertension in Spain is 50% 3. It is assumed 
that the prevalence of controlled hypertension in the 
control group at the end of the study will not change from 
baseline (π1=0.50) and an increase of 25% in the prevalence 
of controlled hypertensive patients in the intervention 
group after the 6 months of follow-up will occur (π2=0.75). 
A comparing two binomial proportion test was applied, 
using a statistical table for the design of clinical trials35, 
considering the following assumptions: type II error 20% 
(ß = 0.80), 95% significance level (α = 0.05).
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The contemplated sample size thus included 58 patients in 
each group (116 in total). To this number we added 20% 
(24 patients) to make up for possible losses during the 
study. The final total number of subjects (n=140) will be 
equally distributed among the 18 participating pharmacists 
(approximately 10 subjects per pharmacist). The decision 
to assign 10 patients per pharmacist was based on the 
experience of other authors, who suggest working with 10-
20 patients as a reasonable number for conducting patient 
healthcare activities at the pharmacy36.
Trial population and recruitment. Patient screening will 
be performed on a consecutive basis as the patients visit the 
pharmacy to receive their antihypertensive drug. Due to the 
existence of drugs being prescribed either for hypertension 
or heart failure, the pharmacist will consult the patient’s 
medical report in order to check the therapeutic indication. 
This personal medical report includes information such as: 
reason of medical consultation, medical diagnosis, medical 
tests performed, pharmacological treatments applied and 
non-pharmacological advice. If the patient does not have a 
medical record, the pharmacist will contact the physician 
in order to inquire about therapeutic indication on the 
drugs prescribed.
The pharmacists will identify patients consecutively until 
they have recruited 10 subjects. The recruitment stage will 
be fixed at a maximum of one month. Patient inclusion is 
contingent on their acceptance to participate in the study 
and the study’s inclusion criteria. The assignment method 
will consist of a coin toss to determine the group assignment 
of the first recruited patient per pharmacist. This will be 
done in each pharmacy. As the aim is to divide the patients 
evenly between the two groups (ncontrol = nintervention), the 
assignment of the first patient will determine the group of 
subsequent patients into the intervention or control groups 
(for example, control/intervention/control/intervention, 
etc.). This process will be continued until there are10 
subjects per pharmacist. The assignment method will only 
be known to the study coordinator at the beginning of the 
study. 
To minimize the risk of selection bias, after visits 1, 2 and 3 
(initial phase, see figure 1) the participating pharmacist will 
contact the study coordinators to determine the assignment 
of the patient to the control or intervention group. The 
pharmacist will contact the coordinators as each patient is 
included in the study to ascertain their group assignment. 
The assignment details were revealed to patients as well 
as study pharmacists only after the completion of baseline 
data collection. 
1.Variables related to the study objectives: primary outcome 
variables.
BP at the pharmacy. It will be monitored in two different 
periods: at the start and end of the study (figure 1). In each 
period, BP will be recorded on three visits scheduled in 
the same timeline of the day. The time period for the three 
visits to the pharmacy will cover three weeks. On each visit 
three BP measurements will be made spaced 2-3 minutes 
apart, on the control arm (the arm where BP is highest). All 
pharmacists will use the same clinically validated Visomat 
Comfort 20/40 monitor (UEBE Medical GmbH, Wertheim, 
Germany)37.
The pharmacists were previously instructed on how 
to monitor BP adequately according to international 
guidelines38: 5 minutes at rest, back supported with feet 
flat on the floor, proper cuff size at heart level, refrain 
from drinking coffee or tea, smoking or exercise at least 30 
minutes prior to measurement.
Depending on the objective, BP values will be used in their 
original form (objective 2) or BP will be transformed on a 
dichotomic basis: controlled / uncontrolled (objective 1).
Mean BP and heart rate in the pharmacy will be calculated, 
rejecting the measurements obtained on the first day and 
the first measurement of the next two days. BP control will 
be defined as systolic BP under 140 mmHg and diastolic BP 
under 90 mmHg. 
Medication adherence. It will be recorded in two different 
periods: at the start and end of the study (figure 1), based on 
manual pill count of antihypertensive tablets. This method 
is an objective and reliable method to assess and investigate 
adherence to drug therapy in clinical practice39-41.
A count will be made at the start and end, spaced one 
month apart. On occasion of the initial count, the date, 
total number of tablets in the possession of the patient, and 
number of tablets retrieved with the new prescriptions, if 
any, will be recorded. After 28-30 days, the patient will be 
asked to return the drug packs with the complete blisters 
(consumed or otherwise), and the tablets will be counted 
(those missing being taken to have been consumed). From 
this point, calculation will be made of the total number of 
tablets apparently consumed by subtracting the remaining 
tablets at the final count from the total tablets at the 
initial count. Likewise, calculation will be made of the 
total number of tablets that should have been consumed: 
tablets a day prescribed, multiplied by the number of days 
elapsed. Lastly, adherence will be measured as percent 
medication adherence (PMA), calculated by means of the 
following formula: 
PMA= (Total number. of apparently consumed tablets/ 
Total number. of tablets that should have been consumed) 
x 100. Dichotomic transformation of PMA will be used: 
adherent / non- adherent. Adherence will be defined as 
PMA 80-110%. 
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2. In addition to the abovementioned variables, other 
variables will be recorded at both the start and end of the 
study, allowing us to describe the study sample and adjust 
the pharmaceutical intervention effect upon hypertension 
control, the decrease in systolic/diastolic BP, and 
medication adherence (evaluation of confounding factors). 
These variables are the following: 
- Age (continuous variable), expressed in years; sex.
- Sociocultural level (polychotomic variable): illiterate / 
primary education / secondary education or technical 
training / university.
- Occupational status (polychotomic variable): housewife 
/ employed / student / unemployed.
- Marital status (dichotomic variable): with / without 
couple.
- Smoking (dichotomic variable): smoker / non-smoker. 
Smokers will be defined as those subjects who regularly 
smoke any amount of cigarettes, or who have stopped 
smoking less than a year ago.
- Physical exercise (dichotomic variable): yes / no. 
Physical exercise will be defined as walking or any form 
of aerobic exercise for an average of half an hour a day, 
three times a week.
- Number of antihypertensive drugs (continuous 
variable).
- Types of antihypertensive drugs (polychotomic 
variable): diuretics, beta-blockers, alpha-blockers, 
calcium antagonists, angiotensin-converting enzyme 
inhibitors (ACEIs) / angiotensin II receptor antagonists 
(ARA II) / others.
- Number of antihypertensive drug doses/day 
(continuous variable).
- Weight (continuous variable), expressed in kg.
- Height (continuous variable), expressed in cm. 
In addition, the presence of the following conditions 
will be documented at the start of the study: diabetes, 
acute myocardial infarction, chest pain, heart failure, 
stroke, peripheral artery disease, hypercholesterolemia, 
hypertriglyceridemia.
Operating procedures: visit scheduling. In broad outlines, 
the operating procedures can be divided into three main 
phases: (1) initial phase; (2) final phase, in which pharmacist 
intervention will be the same in both groups; and (3) 
intermediate phase, in which the control group will receive 
the usual pharmacy care and the intervention group will 
receive the pharmaceutical intervention designed to the 
effect.
Initial study phase. Intervention and control group.
The initial phase comprises three visits scheduled in 
three consecutive weeks (figure 1), in which the following 
activities will be performed: (1) BP measurement at the 
pharmacy; (2) collection of the initial patient data; (3) 
checking of the exclusion criteria; (4) signing of the informed 
consent sheet; and (5) start of manual tablet count.
Intermediate study phase. The intermediate phase will 
begin once assignment of the patient to the control or 
intervention group is known. Tablet counting will end on 
the first visit of this phase (independently of the group to 
which the patient has been assigned). 
After this visit the patients in the control group will not 
be appointed until 20 weeks later. During this period, the 
pharmacist will attend these patients as usually done at the 
pharmacy.
In turn, the patients in the intervention group will start 
the pharmaceutical intervention program. Thus, on the 
first visit of the intermediate phase, the patients will be 
instructed on the use of HBPM in a 20-minute training 
session by their pharmacist. At the end of the session, the 
HBPM technique will be tested by three consecutive self-
measurements made in the presence of the pharmacist. 
Patients will also receive written guidelines to reinforce the 
training provided. Patients will monitor their HBPM over 
a 5-day period, taking three measurements in the morning 
(each measurement spaced 2 minutes apart, between 6.00 
a.m. and 9.00 a.m.) and three in the evening (between 6.00 
p.m. and 9.00 p.m.). At home, the same device as in the 
pharmacy will be used. 
After this first visit, the patients will have 5 additional 
planned visits over a period of 5 months. 
On the second visit of this intermediate phase, the patients 
will be instructed (verbally and in writing) on aspects 
related to adherence, using an information leaflet designed 
to the effect. In this context, the pharmacist will try to 
identify the educational needs of each patient by means 
of a specifically designed questionnaire (appendix 1), in 
order to individualize and better adapt the educational 
intervention to these needs. 
On this same visit, the mean systolic / diastolic BP value 
of the 5 days of home measurement will be assessed. If 
the recorded value is ≥ 135/85 mmHg, the patient will 
be referred to the physician with a personalized report, 
for introduction of the treatment adjustments considered 
appropriate. The patient will be seen again four weeks 
later (visit 3). It will be determined whether the physician 
has made any treatment changes, and the patient will be 
asked to continue HBPM at least one day a week.
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Four weeks later (visit 4), the patient again will be asked 
to continue HBPM for 5 consecutive days, in order to 
again assess the efficacy of the antihypertensive treatment 
received.
At the end of HBPM, the mean home BP value will be 
assessed, and the patient will be referred to the physician if 
≥ 135/85 mmHg (visit 5). 
Four weeks later (visit 6), it will be checked whether the 
patient complies with HBPM, and whether the physician 
has introduced treatment changes.
 Final study phase. The final study phase will take place 6 
months after patient inclusion in the study. This final phase 
will include four visits involving a new tablet count, and 
BP again will be measured in the pharmacy in the course 
of three scheduled visits (figure 1).
Statistical analysis. The data will be filed and analyzed 
using the SPSS version 15.0 statistical package for Microsoft 
Windows (SPSS Inc., Chicago, Illinois, USA). 
The sample characteristics will be described based on 
frequency tables for the qualitative variables and tendency 
measures (arithmetic mean and standard deviation) for 
the quantitative variables. In addition, the 95% confidence 
intervals will be calculated.
The Student t-test for paired samples will be used to 
compare means of one same group between the start and 
end of the study. If the test application conditions are not 
met, a nonparametric test will be used: the Wilcoxon test. 
The McNemar test will be used to compare proportions of 
one same group between the start and end of the study.
The Student’s test for independent samples will be 
used to compare means between the control group and 
the intervention group, provided the test applicability 
conditions are met. Otherwise, the Welch test would be 
used (for two means that follow a normal distribution, but 
which show heterogeneous variances). If the applicability 
conditions of this test are not met, a nonparametric test will 
be used: Mann-Whitney U-test. The chi-squared test in turn 
will be used to compare proportions between the control 
group and the intervention group. When the chi-squared 
test cannot be used because some expected frequency in the 
2 x 2 tables is ≤ 5, the Fisher’s exact test will be applied.
Multivariate logistic regression analysis will be used to 
evaluate the effect of the pharmaceutical intervention. To 
this effect, two models will be developed: one where the 
dependent variable is BP control at the end of the study, 
and another where the dependent variable is medication 
adherence at the end of the study. The following variables 
will be entered in both models to control the effect of the 
intervention: age, sex, body mass index, physical exercise, 
number of antihypertensive drugs, presence of diabetes, 
presence of cardiovascular disease (acute myocardial 
infarction, chest pain, angina pectoris, stroke and/or 
peripheral artery disease), presence of dyslipidemia 
(hypercholesterolemia and/or hypertriglyceridemia), and 
initial BP values.
Likewise, evaluation will be made of the effect of the 
intervention upon the lowering of BP. To this effect, two 
analysis of covariance (ANCOVA) will be developed in 
which the dependent variables will be systolic and diastolic 
BP, respectively. 
Ethics and trial registration. Patient participation is 
voluntary, and all subjects will give informed consent.
The AFenPa study was evaluated and approved by the 
Clinical Research Ethics Committee of the University of 
Granada (Spain). 
DISCUSSION
To our knowledge, this is the first study in the community 
pharmacy setting in Spain to evaluate the effectiveness of 
pharmaceutical intervention together with home HBPM 
upon BP control. In addition, the drug intervention 
has been designed for inclusion as routine community 
pharmacy practice.
Study limitations.  The AFenPA study is a pilot study, whose 
aim is to assess on the effect of a specific pharmaceutical 
intervention in a community pharmacy setting. It should be 
noted that, although quasi-experimental studies are a valid 
alternative to randomized control trial in the evaluation 
of health interventions, in future studies a randomized 
control trial design should be performed. Caution should 
be exercised when interpreting our results as behavioural 
intervention studies run the risk of contamination between 
the intervention and the control groups happening. Other 
limitations include short-term assessment of BP control and 
treatment adherence. Caution should be exercised when 
interpreting our results as behavioural intervention studies 
run the risk of contamination between the intervention and 
the control groups happening. Furthermore, in this study 
researchers who conduct the intervention are not blinded.
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Figure 1. General Procedure of the study.
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